PAM Pathway
Overactivation of the PAM (PI3K/AKT/mTOR) pathway plays a key role in the progression of a wide variety of human cancers.
REVTORPYK™ (gedatolisib) is FDA-approved as a 2nd-line treatment for HR+/HER2-PIK3CA wild-type advanced breast cancer.
Our Pipeline
We are evaluating gedatolisib across a range of solid tumors to improve patient outcomes.
Clinical Trials
We have multiple ongoing clinical trials for gedatolisib as a potential treatment for breast and prostate cancer.
Recent News
October 5, 2026
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
October 2, 2026
Celcuity Appoints David Gryska To Its Board Of Directors
September 30, 2026
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States